Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Jardiance

Study type: Observational

Funder types: Industry

Identifiers

NCT02489942

1245.94

Details and patient eligibility

About

Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus

Enrollment: 8,145 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Male and female Japanese patients with type 2 diabetes mellitus who have never been treated with JARDIANCE® Tablets before the enrolment

Exclusion criteria

None

Trial design

8,145 participants in 1 patient group

Jardiance

Description:

Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg

Treatment:

Drug: Jardiance